Clinical Trials
90
31 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Active, not recruiting
31
34.4%
Completed
5
5.6%
Recruiting
53
58.9%
Withdrawn
1
1.1%
No approval data available
- A French phase III trial (UNICANCER HypoG-01) demonstrated that 3-week hypofractionated radiotherapy was noninferior to standard 5-week treatment in preventing lymphedema in early breast cancer patients. - The study of 1,221 women showed comparable lymphedema rates between 3-week (23.4%) and 5-week (22.2%) radiotherapy regimens with similar safety profiles. - Ultra-hypofractionated radiotherapy using just 5 fractions proved feasible in locally advanced breast cancer, with 46.6% of patients showing favorable clinical response rates. - These findings support shorter radiation treatment courses that could improve patient convenience while maintaining therapeutic efficacy and safety.
- The CAPItello-281 phase 3 trial demonstrated that adding capivasertib to standard therapy prolonged radiographic progression-free survival by 7.5 months in patients with PTEN-deficient metastatic hormone-sensitive prostate cancer. - The combination achieved a median rPFS of 33.2 months compared to 25.7 months with placebo, representing a statistically significant 19% reduction in disease progression risk. - Greater PTEN deficiency correlated with increased treatment benefit, with patients showing 100% PTEN loss experiencing the most pronounced survival improvements. - The safety profile showed manageable toxicities, with diarrhea, hyperglycemia, and rash being the most common adverse events in the capivasertib arm.
- Rechallenge with a different first-generation RET inhibitor after toxicity-related discontinuation achieved a 50% objective response rate and 9.89-month median progression-free survival in RET-rearranged NSCLC patients. - The retrospective multicenter study from the RET MAP registry demonstrated that switching to a different RET inhibitor of the same class remains effective after initial treatment discontinuation due to side effects. - RET inhibitor rechallenge after disease progression showed limited efficacy as monotherapy with only 18% response rate, though combination therapies targeting bypass resistance showed some promise. - The findings provide new evidence for treatment sequencing in RET-rearranged NSCLC, a rare subset affecting 1-2% of advanced lung cancer patients with limited therapeutic options.
- Johnson & Johnson announced first-in-human Phase 1 results for pasritamig, a novel bispecific T-cell engager targeting KLK2, showing promising anti-tumor activity in metastatic castration-resistant prostate cancer patients. - The study demonstrated a favorable safety profile with 40% of patients experiencing no treatment-related adverse events and no treatment discontinuations due to toxicity. - Among 33 patients in the efficacy group, 42.4% achieved ≥50% PSA reduction with a median radiographic progression-free survival of 7.9 months. - The drug's convenient once-every-six-weeks outpatient dosing schedule represents a potential advantage for community-based cancer care delivery.
- 3D printing technology is emerging as a critical innovation in pharmaceutical manufacturing, enabling precise drug delivery systems with micron-level features that traditional manufacturing methods cannot achieve. - Recent implementations include the world's first study using pharmaceutical 3D printers for compounding minoxidil medications in retail pharmacies, reducing pharmacist involvement time by 55% while maintaining quality standards. - Hospital pharmacies, including Europe's leading cancer research hospital Institut Gustave Roussy, are utilizing 3D printing to manufacture personalized multi-drug formulations for clinical trials, producing 200 capsules in just 45 minutes. - New regulatory frameworks for distributed manufacturing of 3D-printed medications are developing globally, with the UK introducing "modular manufacture" legislation effective summer 2025, marking a significant shift in pharmaceutical production paradigms.
- Final analysis of COSMIC-313 phase 3 trial demonstrates sustained progression-free survival benefit with cabozantinib-nivolumab-ipilimumab combination in advanced RCC patients. - The triplet therapy showed no significant overall survival advantage compared to the control arm in intermediate- or poor-risk advanced renal cell carcinoma patients. - Study conducted at Institut Gustave Roussy provides important insights into the role of combination immunotherapy approaches in advanced kidney cancer treatment.
- Five-year analysis of ESTIMABL2 trial demonstrates thyroidectomy without radioiodine is noninferior to radioiodine administration in low-risk differentiated thyroid cancer, with event-free survival rates of 93.2% versus 94.8% respectively. - Patients who did not receive radioiodine showed higher rates of excellent treatment response (83.3%) compared to the radioiodine group (75.6%), according to American Thyroid Association criteria. - The landmark study, involving 776 patients, provides evidence that omitting radioiodine after thyroidectomy does not compromise treatment outcomes in selected low-risk thyroid cancer patients.
- A phase 3 trial (HypoG-01) demonstrated that moderately hypofractionated locoregional radiation therapy is non-inferior to standard normofractionated radiation therapy for early breast cancer patients. - The 5-year cumulative incidence of arm lymphedema was comparable between the hypofractionated (33.3%) and normofractionated (32.8%) radiotherapy arms. - Hypofractionated radiotherapy did not show detrimental effects on survival outcomes, local recurrence-free survival, or distant disease-free survival. - The findings suggest a shift towards a 3-week hypofractionated regimen, even for nodal radiotherapy, potentially reducing treatment burden and healthcare costs.
